Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 May 18;8(Suppl 2):35-8.
doi: 10.4137/BIC.S31804. eCollection 2016.

Targeted Radionuclide Therapy: Practical Applications and Future Prospects

Affiliations
Review

Targeted Radionuclide Therapy: Practical Applications and Future Prospects

Katherine Zukotynski et al. Biomark Cancer. .

Abstract

In recent years, there has been a proliferation in the development of targeted radionuclide cancer therapy. It is now possible to use baseline clinical and imaging assessments to determine the most effective therapy and to tailor this therapy during the course of treatment based on radiation dosimetry and tumor response. Although this personalized approach to medicine has the advantage of maximizing therapeutic effect while limiting toxicity, it can be challenging to implement and expensive. Further, in order to use targeted radionuclide therapy effectively, there is a need for multidisciplinary awareness, education, and collaboration across the scientific, industrial, and medical communities. Even more important, there is a growing understanding that combining radiopharmaceuticals with conventional treatment such as chemotherapy and external beam radiotherapy may limit patient morbidity while improving survival. Developments in radiopharmaceuticals as biomarkers capable of predicting therapeutic response and targeting disease are playing a central role in medical research. Adoption of a practical approach to manufacturing and delivering radiopharmaceuticals, assessing patient eligibility, optimizing post-therapy follow-up, and addressing reimbursement issues will be essential for their success.

Keywords: oncology; radionuclide therapy; targeted.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Seidlin SM, Marinelli LD, Oshry E. Radioactive iodine therapy: effect on functioning metastases of adenocarcinoma of the thyroid. J Am Med Assoc. 1946;132:838–847. - PubMed
    1. Larson SM, Carrasquillo JA, Krohn KA, et al. Localization of 131I-labeled p97-specific Fab fragments in human melanoma as a basis for radiotherapy. J Clin Invest. 1983;72:2101–2114. - PMC - PubMed
    1. Crawford LM. New therapy for non-Hodgkin lymphoma. JAMA. 2002;287(13):1640. - PubMed
    1. Goldsmith SJ. Radioimmunotherapy of lymphoma: Bexxar and Zevalin. Semin Nucl Med. 2010;40(2):122–135. - PubMed
    1. Brady D, O’Sullivan JM, Prise KM. What is the role of the Bystander response in radionuclide therapies? Front Oncol. 2013;3:215. - PMC - PubMed